-
公开(公告)号：US09815890B2
公开(公告)日：2017-11-14
申请号：US13805522
申请日：2011-06-22
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , C07K14/47
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
-
22.发明授权Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles 有权使用CR2靶向纳米颗粒的非侵入性检测补体介导的炎症公开(公告)号：US08840868B2
公开(公告)日：2014-09-23
申请号：US13148028
申请日：2010-02-04
CPC分类号： A61K49/1812 , A61K49/16 , A61K49/1863 , A61K49/1866 , A61K49/1875 , A61K49/1887 , B82Y5/00
摘要： Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided.
摘要翻译： 提供补体介导炎症的非侵入性成像方法。 还提供了包括用于这些方法的CR靶向超小超顺磁性纳米颗粒或其聚集体的组合物。
-
公开(公告)号：US20130078245A1
公开(公告)日：2013-03-28
申请号：US13589079
申请日：2012-08-17
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
摘要翻译： 本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向预防性或 治疗剂可以与身体内的组织的局部区域相比，其可以以非靶向的系统方式与相同或相似的药物的给药相比，其可以更直接地将其作用发挥到预定的靶细胞或组织上，具有减少的相关系统效应。 因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。 本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。
-
公开(公告)号：US20120014952A1
公开(公告)日：2012-01-19
申请号：US13162479
申请日：2011-06-16
IPC分类号： A61K39/395 , C07K14/705 , A61K38/17 , A61P29/00 , A61P31/04 , A61P31/10 , A61P33/00 , A61P35/00 , C07K19/00 , A61P31/12
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
-
公开(公告)号：US07964705B2
公开(公告)日：2011-06-21
申请号：US12049233
申请日：2008-03-14
申请人： Woodruff Emlen , V. Michael Holers , Peter Flynn
发明人： Woodruff Emlen , V. Michael Holers , Peter Flynn
IPC分类号： C12P21/08
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/18 , C07K16/461 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.
摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。
-
-
-
-
搜索结果
25 条记录 (耗时 0.033 秒)
